Skip to main content
Top
Published in: Diabetologia 10/2017

01-10-2017 | Article

The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study

Authors: Ionut Bebu, Barbara H. Braffett, Rodica Pop-Busui, Trevor J. Orchard, David M. Nathan, John M. Lachin, the DCCT/EDIC Research Group

Published in: Diabetologia | Issue 10/2017

Login to get access

Abstract

Aims/hypothesis

Chronic hyperglycaemia, as measured by HbA1c levels, is a major risk factor for atherosclerosis and cardiovascular disease (CVD) in type 1 diabetes. Our aim was to describe the degree to which the effect of HbA1c on the risk of CVD is mediated by its effect on traditional risk factors over time, and how these mediation pathways change over time.

Methods

The DCCT and its observational follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), followed 1441 participants for a mean of 27 years, with periodic measurement of HbA1c and risk factors over time. We assessed the proportion of the HbA1c effect on risk of CVD that was mediated through its effects on systolic BP (SBP), pulse rate, triacylglycerols and LDL-cholesterol (LDLc) levels, and how the proportion mediated changed over time.

Results

The association of HbA1c with CVD outcomes was stable over time, while that of traditional risk factors (SBP, pulse rate, triacylglycerols and LDLc) increased. At 10 years of follow-up, the effect of HbA1c on 10 year CVD risk was minimally mediated by SBP (2.7%), increasing to 26% at 20 years. Likewise, from 10 year follow-up to 20 year follow-up, the proportion of HbA1c effect mediated through pulse rate increased from 6.3% to 29.3%, through triacylglycerols from 2.2% to 22.4%, and through LDLc from 9.2% to 30.7%.

Conclusions/interpretation

As participants age, the predictive association of mean HbA1c on subsequent CVD events is increasingly mediated by its effect on standard risk factors. Thus, management of traditional non-glycaemic CVD risk factors may have increasing benefits in an ageing type 1 diabetes population with longstanding hyperglycaemia.
Trial registration: ClinicalTrials.​gov NCT00360893 and NCT00360815.
Appendix
Available only for authorised users
Literature
1.
go back to reference Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538CrossRefPubMed Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538CrossRefPubMed
2.
go back to reference Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321CrossRefPubMedPubMedCentral Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321CrossRefPubMedPubMedCentral
3.
go back to reference Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653CrossRefPubMed Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653CrossRefPubMed
4.
go back to reference Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39:686–693CrossRef Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39:686–693CrossRef
5.
go back to reference Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group (2016) Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 65:1370–1379CrossRef Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group (2016) Risk factors for cardiovascular disease in type 1 diabetes. Diabetes 65:1370–1379CrossRef
6.
go back to reference Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS (2007) Diabetes control and complications trial/epidemiology of diabetes interventions and complications research group: the effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 30:2107–2112CrossRefPubMedPubMedCentral Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS (2007) Diabetes control and complications trial/epidemiology of diabetes interventions and complications research group: the effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 30:2107–2112CrossRefPubMedPubMedCentral
7.
go back to reference de Boer IH, Rue TC, Cleary PA et al (2011) Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Arch Intern Med 171:412–420CrossRefPubMedPubMedCentral de Boer IH, Rue TC, Cleary PA et al (2011) Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Arch Intern Med 171:412–420CrossRefPubMedPubMedCentral
8.
go back to reference The DCCT/EDIC Research Group (1999) Epidemiology of diabetes interventions and complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care 22:99–111CrossRef The DCCT/EDIC Research Group (1999) Epidemiology of diabetes interventions and complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care 22:99–111CrossRef
9.
go back to reference The DCCT Research Group (1986) The diabetes control and complications trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 35:530–545CrossRef The DCCT Research Group (1986) The diabetes control and complications trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 35:530–545CrossRef
10.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
11.
go back to reference Lachin JM, Orchard TJ, Nathan DM (2014) DCCT/EDIC research group: update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:39–43CrossRefPubMed Lachin JM, Orchard TJ, Nathan DM (2014) DCCT/EDIC research group: update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:39–43CrossRefPubMed
12.
go back to reference Martinussen T, Scheike TH (2006) Dynamic regression models for survival data. Springer, New York Martinussen T, Scheike TH (2006) Dynamic regression models for survival data. Springer, New York
13.
go back to reference D'Agostino RBS, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation 117:743–753CrossRefPubMed D'Agostino RBS, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation 117:743–753CrossRefPubMed
14.
go back to reference Goff DC Jr, Lloyd-Jones DM, Bennett G et al (2014) American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 63:2935–2959CrossRefPubMed Goff DC Jr, Lloyd-Jones DM, Bennett G et al (2014) American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 63:2935–2959CrossRefPubMed
15.
go back to reference Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61:92–105CrossRefPubMed Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC curves. Biometrics 61:92–105CrossRefPubMed
16.
go back to reference Lange T, Hansen JV (2011) Direct and indirect effects in a survival context. Epidemiology 22:575–581CrossRefPubMed Lange T, Hansen JV (2011) Direct and indirect effects in a survival context. Epidemiology 22:575–581CrossRefPubMed
Metadata
Title
The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study
Authors
Ionut Bebu
Barbara H. Braffett
Rodica Pop-Busui
Trevor J. Orchard
David M. Nathan
John M. Lachin
the DCCT/EDIC Research Group
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4374-4

Other articles of this Issue 10/2017

Diabetologia 10/2017 Go to the issue

Up front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine